Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

1.3K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.3K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

427
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
427
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

305
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
305
Specialized Characteristics of Cardiac Muscles01:27

Specialized Characteristics of Cardiac Muscles

3.9K
The primary role of cardiac muscles is to propel blood throughout the cardiovascular system. The cardiac muscle cells, or cardiomyocytes, exhibit specialized characteristics that allow them to perform this function.
Cardiac muscle cells are smaller than skeletal muscles, averaging 10–20 mm in diameter and 50–100 mm in length. However, they have large energy demands for continuous contraction and relaxation. This energy is almost exclusively derived from aerobic metabolism of energy...
3.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

354
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
354

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial.

Journal of cardiac failure·2018
Same author

Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review.

JACC. Heart failure·2018
Same author

The Vulnerable Phase of Heart Failure.

American journal of therapeutics·2018
Same author

Optimal Endpoints of Acute Heart Failure Therapy.

American journal of therapeutics·2018
Same author

Improving Postdischarge Outcomes in Acute Heart Failure.

American journal of therapeutics·2018
Same author

Epirubicin and long-term heart failure risk in breast cancer survivors.

European journal of heart failure·2018

相关实验视频

Updated: Jan 6, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.7K

心脏收缩度调制:一个更新.

Jürgen Kuschyk1, Javed Butler2, Timothy Fendler3

  • 1Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. juergen.kuschyk@umm.de.

Herzschrittmachertherapie & Elektrophysiologie
|October 30, 2025
PubMed
概括

心脏收缩性调制 (CCM) 为心力衰竭 (HF) 患者提供了一种新的设备治疗方法. 这种创新的治疗方法增强了心肌收缩和放松,改善了患者的治疗结果.

关键词:
在CCM-D中,我们可以使用CCM.défibrillator 的功能可以使用.心脏衰竭是因为心脏衰竭.心力衰竭与保存的喷射分数的心脏衰竭心力衰竭与减少的喷射分数心力衰竭.

更多相关视频

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.4K
Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

15.4K

相关实验视频

Last Updated: Jan 6, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.7K
Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.4K
Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

15.4K

科学领域:

  • 心脏病学 心脏病学
  • 生物医学工程 生物医学工程
  • 医疗器械 医疗器械

背景情况:

  • 心力衰竭 (HF) 仍然是一个重大的健康负担,尽管有指导方针导向医学治疗 (GDMT),但许多患者有症状.
  • 心脏收缩性调制 (CCM) 是一种新兴的基于设备的疗法,旨在改善HF患者的心脏功能.
  • CCM提供非刺激性的电信号,以增强心肌收缩性和放松性.

研究的目的:

  • 审查CCM在HF患者的治疗效果和安全性,减少喷射分数 (HFrEF).
  • 要总结AIM HIGHer试验的设计和目标,用于轻度减少 (HFmrEF) 或保存射出分数 (HFpEF) 的高压.
  • 介绍下一代CCM设备与除器功能 (CCM-D) 并讨论INTEGRA-D试验目标.

主要方法:

  • 在HFrEF中对CCM进行临床研究和现实世界的数据进行审查.
  • 在HFmrEF和HFpEF中对AIM HIGHer试验的研究设计的描述.
  • 介绍了CCM-D设备和INTEGRA-D临床研究协议.

主要成果:

  • 研究了HFrEF患者中CCM的治疗益处和安全概况.
  • 目前正在进行的试验 (AIM HIGHer,INTEGRA-D) 正在研究在更广泛的高频群体和具有先进设备功能的CCM.
  • CCM增强了循环和透静的重新吸收,有助于改善心脏功能.

结论:

  • CCM对于症状性HF患者来说是一个有前途的治疗方法,目前正在进行的研究正在扩大其应用.
  • 开发CCM-D设备的目的是提供收缩度调制和除.
  • 未来的研究将进一步阐明CCM在各种HF表型中的作用以及其与其他疗法的结合.